WallStreetZenWallStreetZen

NASDAQ: CALC
Calcimedica Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CALC

Based on 1 analyst offering 12 month price targets for Calcimedica Inc

Min Forecast
$10.00+1,258.7%
Avg Forecast
$10.00+1,258.7%
Max Forecast
$10.00+1,258.7%

Should I buy or sell CALC stock?

Based on 1 analyst offering ratings for Calcimedica Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CALC stock forecasts and price targets.

CALC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-05

1 of 1

Forecast return on equity

Is CALC forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is CALC forecast to generate an efficient return on assets?

Company
-276.08%
Industry
-5.87%
CALC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CALC earnings per share forecast

What is CALC's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.77
Avg 2 year Forecast
-$1.17
Avg 3 year Forecast
-$1.50

CALC revenue forecast

What is CALC's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$3.6M

CALC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CALC$0.74$10.00+1,258.70%Buy
KPRX$2.63N/AN/A
CMMB$1.56N/AN/A
GDTC$1.00N/AN/A
PHIO$1.03$14.00+1,259.22%Buy
View Top Biotech Stocks

Calcimedica Stock Forecast FAQ

Is Calcimedica Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CALC) stock is to Buy CALC stock.

Out of 1 analyst, 0 (0%) are recommending CALC as a Strong Buy, 1 (100%) are recommending CALC as a Buy, 0 (0%) are recommending CALC as a Hold, 0 (0%) are recommending CALC as a Sell, and 0 (0%) are recommending CALC as a Strong Sell.

If you're new to stock investing, here's how to buy Calcimedica stock.

What is CALC's earnings growth forecast for 2026-2028?

(NASDAQ: CALC) Calcimedica's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.87%.

Calcimedica's earnings in 2026 is -$19,544,000.On average, 5 Wall Street analysts forecast CALC's earnings for 2026 to be -$12,166,064, with the lowest CALC earnings forecast at -$13,314,581, and the highest CALC earnings forecast at -$10,782,156. On average, 4 Wall Street analysts forecast CALC's earnings for 2027 to be -$18,450,520, with the lowest CALC earnings forecast at -$22,139,361, and the highest CALC earnings forecast at -$14,265,622.

In 2028, CALC is forecast to generate -$23,768,138 in earnings, with the lowest earnings forecast at -$30,499,679 and the highest earnings forecast at -$16,256,174.

What is CALC's revenue growth forecast for 2026-2028?

(NASDAQ: CALC) Calcimedica's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.37%.

Calcimedica's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast CALC's revenue for 2026 to be $0, with the lowest CALC revenue forecast at $0, and the highest CALC revenue forecast at $0. On average, 4 Wall Street analysts forecast CALC's revenue for 2027 to be $0, with the lowest CALC revenue forecast at $0, and the highest CALC revenue forecast at $0.

In 2028, CALC is forecast to generate $56,398,971 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $116,115,528.

What is CALC's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: CALC) forecast ROA is -276.08%, which is lower than the forecast US Biotechnology industry average of -5.87%.

What is CALC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CALC price target, the average CALC price target is $10.00, with the highest CALC stock price forecast at $10.00 and the lowest CALC stock price forecast at $10.00.

The Wall Street analyst predicted that Calcimedica's share price could reach $10.00 by Mar 5, 2027. The average Calcimedica stock price prediction forecasts a potential upside of 1,258.7% from the current CALC share price of $0.74.

What is CALC's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CALC) Calcimedica's current Earnings Per Share (EPS) is -$1.30. On average, analysts forecast that CALC's EPS will be -$0.77 for 2026, with the lowest EPS forecast at -$0.84, and the highest EPS forecast at -$0.68. On average, analysts forecast that CALC's EPS will be -$1.17 for 2027, with the lowest EPS forecast at -$1.40, and the highest EPS forecast at -$0.90. In 2028, CALC's EPS is forecast to hit -$1.50 (min: -$1.93, max: -$1.03).

What is CALC's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: CALC) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.